Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal anti-inflammatory effect of cladribine in multiple sclerosis
2018-004947-21Phase 4Completed
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine in multiple sclerosis (MS) and relapsing-remitting multiple sclerosis (RRMS), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Started Apr 2020; status: completed.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2018-004947-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004947-21.